PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-1.28
Negative P/E while Biotechnology median is -7.33. Seth Klarman would scrutinize path to profitability versus peers.
No Data
No Data available this quarter, please select a different quarter.
1.48
P/B less than half the Biotechnology median of 3.77. Joel Greenblatt would investigate if assets are truly impaired. Check ROE versus peers.
-5.91
Negative FCF while Biotechnology median P/FCF is -26.82. Seth Klarman would investigate cash flow improvement potential.
-5.91
Negative operating cash flow while Biotechnology median P/OCF is -27.84. Seth Klarman would investigate operational improvement potential.
1.48
Fair value ratio less than half the Biotechnology median of 3.78. Joel Greenblatt would investigate if this discount is justified.
-19.56%
Negative earnings while Biotechnology median yield is -2.30%. Seth Klarman would investigate path to profitability.
-16.93%
Negative FCF while Biotechnology median yield is -1.93%. Seth Klarman would investigate cash flow improvement potential.